PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Gentronix recognised with King’s award after record international growth

7 May 2024

UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology firm based at Alderley Park – has been awarded the King’s Award for Enterprise after achieving a triple-figure revenue growth following rapid expansion in international markets.

Gentronix recorded total growth of 239% in overseas earnings over the past three years, with the percentage of total sales exported rising from 71% to 81% over the same period, driving revenue to in excess of £10m per annum. The US has been a particularly strong area of growth and this market now makes up almost half of the firm’s international business, with demand continuing to increase across North America.

As a result of the business’s success and enhanced overseas trading, Gentronix has received a prestigious King’s Award for Enterprise for 2024, marking its success in the area of International Trade.

Along with its UK and US client base, Gentronix also supplies its services to a growing number of international customers including in the EU, Switzerland and Japan.

To support this exceptional growth, the business has also expanded laboratory space at its home at Alderley Park in Cheshire by 30% - an additional 5,000 sq. ft - and increased its headcount to 67, with further investment continuing in 2024 and 2025. Its workforce supports the needs of seven of the top 10 global pharma companies. 

Gentronix’s growth and expansion has further strengthened its ability to support clients in meeting their regulatory requirements, identifying potential hazards within project pipelines and managing risk…

Read More...
Gentronix recognised with King’s award after record international growth

Articles